JAZZ Jazz Pharmaceuticals plc - Ordinary Shares
$252,44
السعر · أغسطس 18, 2026
البيانات الأساسية اعتبارًا من أغسطس 3, 2026
نطاق 52 أسبوعًا
$118–$265
91% of range
تقييم المحللين
BUY
26 analysts
السعر المستهدف
$281
+11% upside
P/E (TTM)
-29.1
ROE
—
هامش صافي الربح
—
حول Jazz Pharmaceuticals plc - Ordinary Shares نظرة عامة على الشركة من ويكيبيديا
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
اقرأ المزيد
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Company history and acquisitions
2010–2019
On 18 February 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia. In the following December, a new patent was issued for Sodium Oxybate.
On September 19, 2011, Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc. The Azur Pharma seat in Dublin became the headquarters of the combined company. Azur Pharma had been marketing specialty pharmaceutical products in the central nervous system (CNS) and women's health areas with US operations in Philadelphia.
On 26 April 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments). In September, the company sold its Women's Health business to Meda for $95 million. In December, the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia.
In January 2014, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.
In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its then largest acquisition, with the purchase of Celator Pharmaceuticals for $1.5 billion. As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.
In August 2019, the company announced it would acquire Cavion Inc. for up to $310 million.
2020–present
In January 2021, Jazz announced it would acquire cannabis-focused medicinal drug company GW Pharmaceuticals for US$7.2 billion. This acquisition added the medication Epidiolex (cannabidiol), developed to treat severe epilepsy syndromes, to the company's portfolio.
In November 2025, Jazz Pharmaceuticals announced positive results from its Phase 3 trial for its cancer drug, Ziihera, a potential treatment for advanced gastroesophageal cancer.
Acquisition history
The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:
== References ==
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
JAZZ لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$252.44
القيمة السوقية
—
P/E (TTM)
-29.1
ربح السهم (آخر 12 شهرًا)
$-5.84
الإيرادات (آخر 12 شهرًا)
$4.27B
عائد التوزيعات
—
ROE
—
D/E الدين/حقوق الملكية
—
نطاق 52 أسبوعًا
$118 – $265
JAZZ مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
Configure
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات وصافي الدخل
$4.27B
2016-12-31
→
2025-12-31
ربح السهم
$-5.84
2016-12-31
→
2025-12-31
التدفق النقدي الحر
—
الهوامش
—
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
المقياس
اتجاه 5 سنوات
JAZZ
متوسط الأقران
P/E (TTM)
-29.1
530.6
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
المقياس
اتجاه 5 سنوات
JAZZ
متوسط الأقران
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
المقياس
اتجاه 5 سنوات
JAZZ
متوسط الأقران
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
المقياس
اتجاه 5 سنوات
JAZZ
متوسط الأقران
Revenue YoY (الإيرادات مقارنة بالعام السابق)
4.9%
—
Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات)
5.3%
—
Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات)
12.5%
—
EPS YoY (ربحية السهم على أساس سنوي)
41.8%
—
Net Income YoY (صافي الدخل مقارنة بالعام السابق)
35.0%
—
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
المقياس
اتجاه 5 سنوات
JAZZ
متوسط الأقران
JAZZ توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
شراء
26 محللين
- شراء قوي 7 26,9%
- شراء 17 65,4%
- احتفاظ 2 7,7%
- بيع 0 0,0%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
20 محللين · 2026-08-15
الوسيط
$285.00
الآن
$252.44
منخفض
$196.00
مرتفع
$315.00
السعر المستهدف الوسيط
$285.00
+12,9%
السعر المستهدف المتوسط
$281.10
+11,4%
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
-0.06%
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $5.71 | $6.30 | -0.59% |
| 31 مارس، 2026 | $6.34 | $4.66 | 1.7% |
| 31 ديسمبر، 2025 | $6.64 | $6.65 | -0.01% |
| 30 سبتمبر، 2025 | $8.13 | $6.04 | 2.1% |
| 30 يونيو، 2025 | $-8.25 | $-7.76 | -0.49% |
| 31 مارس، 2025 | $1.68 | $4.75 | -3.1% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| JAZZ | — | -29.1 | 4.9% | — | — | — |
| GHRS | — | — | — | — | — | — |
| PRGO | $1.92B | -1.4 | -2.8% | -33.5% | -38.5% | 35.1% |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 14
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| R&D Expense | · | · | · | · | · | · | $300M | $227M | $198M | $162M | $135M | $85M | |
| SG&A Expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854M | $737M | $684M | $544M | $503M | $449M | $406M | |
| Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | $896M | $817M | $977M | |
| Operating Income | $-430M | $717M | $579M | $-66M | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | |
| Interest Income | $86M | $106M | $65M | $12M | $2M | $11M | $20M | $17M | $4M | · | · | · | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $1M | $9M | |
| Pretax Income | $-628M | $470M | $298M | $-373M | $-113M | $275M | $454M | $529M | $441M | $532M | $436M | $152M | |
| Income Tax | $-272M | $-91M | $-120M | $-159M | $216M | $34M | $-73M | $80M | $-48M | $135M | $106M | $94M | |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | |
| Shares (Basic) | 60,981,000 | 61,838,000 | 63,291,000 | 62,539,000 | 59,694,000 | 55,712,000 | 56,749,000 | 59,976,000 | 60,018,000 | 60,500,000 | 61,232,000 | 59,746,000 | |
| Shares (Diluted) | 60,981,000 | 66,007,000 | 72,066,000 | 62,539,000 | 59,694,000 | 56,517,000 | 57,550,000 | 61,221,000 | 61,317,000 | 61,870,000 | 63,036,000 | 62,614,000 |
الميزانية العمومية 26
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881M | $591M | $1.06B | $637M | $310M | $386M | $366M | $989M | $684M | |
| Receivables | $831M | $717M | $706M | $651M | $563M | $396M | $356M | $264M | $224M | $234M | $210M | $186M | |
| Inventory | $417M | $480M | $597M | $714M | $1.07B | $95M | $79M | $53M | $43M | $34M | $19M | $30M | |
| Prepaid Expense | $152M | $177M | $185M | $92M | $131M | $62M | $39M | $25M | $23M | $25M | $21M | $13M | |
| Other Current Assets | $324M | $262M | $321M | $267M | $252M | $152M | $79M | $68M | $77M | $29M | $19M | $21M | |
| Current Assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968M | $748M | $1.26B | $1.02B | |
| PP&E (Net) | · | · | · | · | · | $128M | $132M | $200M | $170M | $107M | $86M | $58M | |
| PP&E (Gross) | · | · | · | · | · | $196M | $187M | $250M | $211M | $140M | $109M | $74M | |
| Accum. Depreciation | · | · | · | · | · | $68M | $55M | $50M | $41M | $32M | $24M | $15M | |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B | $958M | $920M | $928M | $948M | $894M | $657M | $703M | |
| Intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B | $2.20B | $2.44B | $2.73B | $2.98B | $3.01B | $1.19B | $1.44B | |
| Other Non-current Assets | $99M | $114M | $67M | $55M | $41M | $26M | $48M | $43M | $16M | $14M | $9M | $16M | |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Accounts Payable | $122M | $78M | $103M | $91M | $100M | $27M | $46M | $41M | $24M | $22M | $22M | $25M | |
| Accrued Liabilities | $1.03B | $911M | $794M | $803M | $666M | $353M | $270M | $265M | $199M | $193M | $164M | $164M | |
| Current Liabilities | $2.24B | $1.04B | $1.54B | $933M | $809M | $654M | $364M | $345M | $294M | $257M | $227M | $217M | |
| Capital Leases | $51M | $39M | $59M | $72M | $87M | $140M | $151M | $0 | · | · | · | · | |
| Deferred Tax | $594M | $677M | $848M | $944M | $1.30B | $130M | $224M | $309M | $383M | $557M | $283M | $375M | |
| Other Non-current Liabilities | $124M | $87M | $105M | $107M | $117M | $101M | $109M | $219M | $177M | $113M | $69M | $38M | |
| Long-term Debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B | $2.09B | $1.61B | $1.60B | $1.58B | $2.03B | $1.19B | $1.34B | |
| Common Stock | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Retained Earnings | $646M | $1.13B | $879M | $734M | $830M | $1.16B | $1.07B | $841M | $918M | $529M | $303M | $35M | |
| AOCI | $-569M | $-948M | $-842M | $-1.13B | $-400M | $-134M | $-223M | $-198M | $-141M | $-317M | $-267M | $-122M | |
| Stockholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B | $1.71B | $1.37B | |
| Liabilities + Equity | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Shares Outstanding | 61,400,000 | 60,600,000 | 62,255,000 | 63,214,000 | 61,633,000 | 56,171,000 | 56,140,000 | 57,704,000 | 58,898,000 | 59,820,000 | 61,305,000 | 60,643,000 |
التدفق النقدي 12
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $42M | $33M | $30M | $30M | $27M | $19M | $15M | $15M | $13M | $12M | $10M | · | |
| Stock-based Comp | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M | $92M | $70M | |
| Deferred Tax | $-445M | $-208M | $-260M | $-292M | $69M | $-137M | $-237M | $-89M | $-226M | $-41M | $-68M | $-49M | |
| Amort. of Intangibles | $655M | $627M | $608M | $599M | $526M | $260M | $355M | $201M | $152M | $102M | $98M | $127M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $779M | $900M | $776M | $799M | $693M | $592M | $532M | $408M | |
| CapEx | $59M | $38M | $24M | $29M | $28M | $15M | $40M | $20M | $29M | $10M | $36M | $36M | |
| Investing Cash Flow | $-1.51B | $-508M | $-163M | $-446M | $-5.21B | $-1.01B | $-155M | $-394M | $-269M | $-1.75B | $-2M | $-1.07B | |
| Stock Repurchased | $125M | $311M | $270M | $54.0K | $0 | $147M | $301M | $524M | $99M | $278M | $62M | $42M | |
| Financing Cash Flow | $-873M | $21M | $-305M | $-529M | $3.97B | $528M | $-294M | $-479M | $-409M | $541M | $-214M | $711M | |
| Net Change in Cash | $-1.02B | $907M | $625M | $290M | $-466M | $420M | $328M | $-76M | $20M | $-623M | $305M | $48M | |
| Taxes Paid | $122M | $115M | $178M | · | · | · | · | · | · | · | · | · |
معدلات النمو 7
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.3% | 9.6% | 17.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 12.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | 41.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | · | 13.1% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | 35.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | · | 20.2% | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 5
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| Net Income TTM | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| P/E | -29.1 | 14.2 | 20.2 | -44.5 | -23.1 | 39.1 | 16.4 | 17.0 | 16.9 | 17.0 | 26.9 | 176.1 | |
| P / Tangible Book | · | · | · | · | · | 18.3 | · | · | · | · | · | · | |
| Earnings Yield | -3.4% | 7.0% | 5.0% | -2.2% | -4.3% | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% | 3.7% | 0.57% |
قائمة الدخل 13
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $898M | $1.09B | $1.05B | $1.02B | $902M | $1.01B | $972M | $957M | $893M | $972M | $941M | |
| SG&A Expense | $389M | $353M | $406M | $531M | $358M | $514M | $369M | $326M | $339M | $352M | $396M | $308M | $341M | $298M | $383M | $358M | |
| Operating Expenses | $960M | $732M | $943M | $1.07B | $1.73B | $954M | $897M | $795M | $824M | $836M | $889M | $800M | $800M | $767M | $1.24B | $916M | |
| Operating Income | $248M | $337M | $255M | $58M | $-686M | $-56M | $191M | $260M | $199M | $66M | $122M | $172M | $158M | $126M | $-263M | $25M | |
| Interest Income | $25M | $23M | $20M | $19M | $19M | $28M | $32M | $26M | $25M | $23M | $21M | $19M | $15M | $11M | $7M | $4M | |
| Pretax Income | $211M | $299M | $208M | $9M | $-736M | $-110M | $133M | $201M | $138M | $-2M | $62M | $100M | $82M | $55M | $-340M | $-60M | |
| Income Tax | $18M | $6M | $5M | $-242M | $-17M | $-18M | $-58M | $-15M | $-31M | $12M | $-33M | $-47M | $-24M | $-15M | $-100M | $-43M | |
| Net Income | $193M | $293M | $203M | $251M | $-718M | $-92M | $191M | $215M | $169M | $-15M | $94M | $147M | $104M | $69M | $-241M | $-20M | |
| EPS (Basic) | $3.05 | $4.73 | $3.28 | $4.14 | $-11.74 | $-1.52 | $3.11 | $3.50 | $2.68 | $-0.23 | $1.50 | $2.33 | $1.63 | $1.09 | $-3.86 | $-0.31 | |
| EPS (Diluted) | $2.78 | $4.43 | $3.34 | $4.08 | $-11.74 | $-1.52 | $2.97 | $3.42 | $2.49 | $-0.23 | $1.40 | $2.14 | $1.52 | $1.04 | $-3.85 | $-0.31 | |
| Shares (Basic) | 63,200,000 | 61,900,000 | -121,888,000 | 60,696,000 | 61,200,000 | 61,000,000 | -124,995,000 | 61,414,000 | 62,882,000 | 62,537,000 | -127,308,000 | 63,114,000 | 63,991,000 | 63,494,000 | -124,547,000 | 62,785,000 | |
| Shares (Diluted) | 69,400,000 | 66,100,000 | -122,798,000 | 61,606,000 | 61,200,000 | 61,000,000 | -129,329,000 | 63,174,000 | 69,625,000 | 62,537,000 | -146,538,000 | 71,293,000 | 73,540,000 | 73,771,000 | -126,584,000 | 62,785,000 | |
| EBITDA | $248M | $337M | · | $58M | $-686M | $-56M | · | $260M | $199M | $66M | · | $172M | $158M | $126M | · | $25M |
الميزانية العمومية 24
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | · | $1.34B | $1.28B | $1.17B | · | $839M | |
| Receivables | $881M | $836M | $831M | $764M | $714M | $653M | $717M | $724M | $698M | $707M | · | $628M | $610M | $624M | · | $601M | |
| Inventory | $443M | $438M | $417M | $483M | $505M | $493M | $480M | $539M | $543M | $577M | · | $612M | $657M | $675M | · | $728M | |
| Prepaid Expense | $200M | $150M | $152M | $147M | $164M | $150M | $177M | $155M | $134M | $123M | · | $110M | $107M | $73M | · | $93M | |
| Other Current Assets | $244M | $285M | $324M | $315M | $298M | $260M | $262M | $354M | $326M | $315M | · | $310M | $272M | $245M | · | $250M | |
| Current Assets | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B | $3.68B | $3.54B | · | $3.25B | $3.01B | $2.78B | · | $2.57B | |
| Goodwill | $1.80B | $1.80B | $1.83B | $1.83B | $1.84B | $1.76B | $1.72B | $1.80B | $1.74B | $1.74B | · | $1.71B | $1.74B | $1.72B | · | $1.59B | |
| Intangibles | $4.03B | $4.20B | $4.43B | $4.57B | $4.77B | $4.72B | $4.76B | $5.14B | $5.08B | $5.24B | · | $5.42B | $5.71B | $5.76B | · | $5.57B | |
| Other Non-current Assets | $86M | $95M | $99M | $103M | $121M | $117M | $114M | $75M | $71M | $71M | · | $76M | $66M | $64M | · | $35M | |
| Total Assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Accounts Payable | $128M | $100M | $122M | $152M | $89M | $96M | $78M | $85M | $97M | $81M | · | $110M | $98M | $125M | · | $102M | |
| Accrued Liabilities | $1.03B | $1.02B | $1.03B | $1.00B | $875M | $1.06B | $911M | $859M | $801M | $827M | · | $770M | $748M | $712M | · | $668M | |
| Current Liabilities | $2.23B | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B | $1.03B | $1.56B | $1.56B | · | $1.57B | $945M | $909M | · | $813M | |
| Capital Leases | $44M | $47M | $51M | $53M | $55M | $39M | $39M | $71M | $68M | $56M | · | $62M | $66M | $72M | · | $73M | |
| Deferred Tax | $529M | $548M | $594M | $629M | $682M | $671M | $677M | $792M | $775M | $810M | · | $841M | $911M | $932M | · | $934M | |
| Other Non-current Liabilities | $141M | $162M | $125M | $109M | $94M | $91M | $87M | $111M | $99M | $97M | · | $127M | $127M | $109M | · | $124M | |
| Long-term Debt | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B | $6.11B | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Total Debt | $4.35B | $5.35B | · | $5.36B | $5.36B | $5.37B | · | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Common Stock | $0 | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $1.13B | $939M | $646M | $443M | $191M | $1.03B | $1.13B | $936M | $871M | $864M | · | $884M | $812M | $803M | · | $974M | |
| AOCI | $-662M | $-651M | $-569M | $-570M | $-486M | $-786M | $-948M | $-603M | $-888M | $-882M | · | $-1.04B | $-867M | $-980M | · | $-1.62B | |
| Stockholders' Equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B | $3.49B | $3.53B | $3.34B | $3.09B | $2.75B | |
| Liabilities + Equity | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Shares Outstanding | 64,800,000 | 62,700,000 | 61,435,000 | 60,740,000 | 60,640,000 | 61,623,000 | 60,631,000 | 60,443,000 | 61,745,000 | 63,028,000 | 62,255,000 | 62,945,000 | · | · | 63,214,000 | · |
التدفق النقدي 10
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $73M | $74M | $71M | $88M | $65M | $68M | $70M | $60M | $57M | $61M | $53M | $56M | $61M | $56M | $62M | $57M | |
| Deferred Tax | $-39M | $-66M | $-63M | $-271M | $-66M | $-44M | $-2M | $-64M | $-75M | $-66M | $-36M | $-79M | $-79M | $-66M | $-145M | $-65M | |
| Amort. of Intangibles | $170M | $172M | $170M | $168M | $162M | $154M | $159M | $157M | $155M | $156M | $152M | $155M | $152M | $150M | $137M | $141M | |
| Operating Cash Flow | $416M | $408M | $363M | $475M | $89M | $430M | $399M | $399M | $331M | $267M | $167M | $307M | $297M | $321M | $342M | $418M | |
| CapEx | $18M | $20M | $17M | $15M | $13M | $14M | $13M | $11M | $7M | $7M | $10M | $4M | $6M | $4M | $9M | $-5M | |
| Investing Cash Flow | $355M | $123M | $-372M | $-328M | $-641M | $-169M | $-193M | $214M | $-257M | $-272M | $102M | $-174M | $-86M | $-5M | $-324M | $5M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $150M | · | · | $100M | $74M | · | · | $0 | $0 | |
| Financing Cash Flow | $-994M | $-78M | $75M | $-11M | $-125M | $-814M | $-8M | $246M | $-161M | $-57M | $-100M | $-78M | $-97M | $-30M | $20M | $-289M | |
| Net Change in Cash | $-224M | $452M | $66M | $136M | $-672M | $-551M | $195M | $862M | $-88M | $-63M | $171M | $53M | $114M | $286M | $42M | $128M | |
| Free Cash Flow | · | $388M | · | · | · | $416M | · | · | · | $260M | · | · | · | $317M | · | · |
الربحية 7
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| Net Margin | 16.0% | 27.4% | · | 22.3% | -68.7% | -10.3% | · | 20.4% | 16.5% | -1.6% | · | 15.1% | 10.9% | 7.8% | · | -2.1% | |
| Pretax Margin | 17.5% | 28.0% | · | 0.80% | -70.3% | -12.2% | · | 19.0% | 13.5% | -0.18% | · | 10.2% | 8.5% | 6.2% | · | -6.4% | |
| EBITDA Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| ROA | 1.8% | 2.5% | · | 2.1% | -6.4% | -0.81% | · | 1.8% | 1.5% | -0.13% | · | 1.4% | 0.93% | 0.61% | · | -0.17% | |
| ROE | 4.5% | 6.7% | · | 6.2% | -19.2% | -2.4% | · | 5.6% | 4.6% | -0.42% | · | 4.7% | 3.1% | 2.0% | · | -0.59% | |
| ROIC | 2.5% | 3.3% | · | 17.2% | -7.4% | -0.49% | · | 2.7% | 2.6% | 5.8% | · | 2.8% | 2.2% | 1.8% | · | 0.08% |
السيولة والملاءة 4
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 2.0 | · | 1.7 | 1.6 | 3.4 | · | 4.3 | 2.4 | 2.3 | · | 2.1 | 3.2 | 3.1 | · | 3.2 | |
| Quick Ratio | 1.1 | 1.2 | · | 0.9 | 0.9 | 2.1 | · | 2.9 | 1.3 | 1.4 | · | 1.2 | 2.0 | 2.0 | · | 1.8 | |
| Debt / Equity | 0.9 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.5 | · | 1.6 | 1.6 | 1.7 | · | 2.1 | |
| LT Debt / Equity | 0.7 | 1.0 | · | 1.1 | 1.2 | 1.3 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 2.1 |
الكفاءة 2
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.5 | 1.4 | · | 1.5 | 1.5 | 1.3 | · | 1.6 | 1.6 | 1.4 | · | 1.6 | 1.6 | 1.5 | · | 1.7 |
التقييم (آخر 12 شهرًا) 13
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.45B | $4.14B | · | $4.12B | $4.02B | $3.88B | · | $3.95B | $3.86B | $3.72B | · | $3.76B | $3.72B | $3.58B | · | $3.53B | |
| Net Income TTM | $19M | $-266M | · | $-345M | $-427M | $276M | · | $516M | $405M | $306M | · | $301M | $189M | $86M | · | $-36M | |
| Market Cap | $15.61B | $11.85B | · | $8.01B | $6.44B | $7.65B | · | $6.73B | $6.59B | $7.59B | · | $8.15B | · | · | · | · | |
| Enterprise Value | $18.35B | $15.36B | · | $12.04B | $10.61B | $11.16B | · | $10.63B | $10.94B | $11.86B | · | $12.53B | · | · | · | · | |
| P/E | -535.5 | -39.8 | · | -22.9 | -14.4 | 29.8 | · | 14.2 | 18.0 | 26.9 | · | 29.5 | 44.3 | 111.7 | · | -225.9 | |
| P/S | 3.5 | 2.9 | · | 1.9 | 1.6 | 2.0 | · | 1.7 | 1.7 | 2.0 | · | 2.2 | · | · | · | · | |
| P/B | 3.3 | 2.6 | · | 2.0 | 1.7 | 1.8 | · | 1.6 | 1.8 | 2.1 | · | 2.3 | · | · | · | · | |
| P / Cash Flow | · | 29.0 | · | · | · | 17.8 | · | · | · | 28.4 | · | · | · | · | · | · | |
| P / FCF | · | 30.5 | · | · | · | 18.4 | · | · | · | 29.2 | · | · | · | · | · | · | |
| EV / EBITDA | 73.9 | 45.6 | · | 209.4 | -15.5 | -199.6 | · | 40.8 | 54.9 | 179.1 | · | 72.7 | · | · | · | · | |
| EV / FCF | · | 39.5 | · | · | · | 26.8 | · | · | · | 45.5 | · | · | · | · | · | · | |
| EV / Revenue | 4.1 | 3.7 | · | 2.9 | 2.6 | 2.9 | · | 2.7 | 2.8 | 3.2 | · | 3.3 | · | · | · | · | |
| Earnings Yield | -0.19% | -2.5% | · | -4.4% | -6.9% | 3.4% | · | 7.0% | 5.5% | 3.7% | · | 3.4% | 2.3% | 0.90% | · | -0.44% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| صافي الدخل | $-356M | $560M | $415M | $-224M | $-330M |
| EPS المخفف | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
📊
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 690 مقدمي إقرار · $9.8B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 143 (+46 مقابل الربع السابق) | 56 (-21 مقابل الربع السابق) | 220 (+20 مقابل الربع السابق) | 190 (+12 مقابل الربع السابق) | +4.4M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| FMR LLC | $846470147 | 3512762 | 8,60% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $731636247 | 3036213 | 7,43% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $657763761 | 2729650 | 6,68% | الأسهم |
| Capital World Investors | $650043082 | 2697610 | 6,60% | الأسهم |
| STATE STREET CORP | $481895662 | 1999816 | 4,89% | الأسهم |
| FULLER & THALER ASSET MANAGEMENT, INC. | $394839917 | 1638544 | 4,01% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $390196222 | 1619274 | 3,96% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $297928728 | 1236065 | 3,03% | الأسهم |
| AMERIPRISE FINANCIAL INC | $260580996 | 1081421 | 2,65% | الأسهم |
| CITADEL ADVISORS LLC | $242578716 | 1006676 | 2,46% | الأسهم |
| Swedbank AB | $233208837 | 967792 | 2,37% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $184072164 | 763880 | 1,87% | الأسهم |
| VICTORY CAPITAL MANAGEMENT INC | $165478678 | 686719 | 1,68% | الأسهم |
| NORGES BANK | $158279458 | 656843 | 1,61% | الأسهم |
| RENAISSANCE TECHNOLOGIES LLC | $135442731 | 562073 | 1,38% | الأسهم |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $129891746 | 539037 | 1,32% | الأسهم |
| Allianz Asset Management GmbH | $122925785 | 510129 | 1,25% | الأسهم |
| GMT Capital Corp | $109279895 | 453500 | 1,11% | الأسهم |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $105278106 | 436893 | 1,07% | الأسهم |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $103893734 | 431148 | 1,06% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $96439086 | 400212 | 0,98% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $95008929 | 394277 | 0,96% | الأسهم |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $89279867 | 370502 | 0,91% | الأسهم |
| Sofinnova Investments, Inc. | $88036221 | 365341 | 0,89% | الأسهم |
| Polaris Capital Management, LLC | $79270937 | 328966 | 0,81% | الأسهم |
| AMERICAN CENTURY COMPANIES INC | $77695234 | 322427 | 0,79% | الأسهم |
| Bank of New York Mellon Corp | $76961481 | 319382 | 0,78% | الأسهم |
| GOLDENTREE ASSET MANAGEMENT LP | $70838675 | 294435 | 0,72% | الأسهم |
| Qube Research & Technologies Ltd | $70056003 | 290725 | 0,71% | الأسهم |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $66815854 | 277279 | 0,68% | الأسهم |
| Quantinno Capital Management LP | $65906960 | 273506 | 0,67% | الأسهم |
| Boston Trust Walden Corp | $64110068 | 266050 | 0,65% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $60589497 | 251440 | 0,62% | الأسهم |
| Tri Locum Partners LP | $53427868 | 221720 | 0,54% | الأسهم |
| Iron Triangle Partners LP | $49668900 | 292170 | 0,50% | الأسهم |
| ARGENT CAPITAL MANAGEMENT LLC | $48211350 | 200072 | 0,49% | الأسهم |
| GOLDMAN SACHS GROUP INC | $45527185 | 188933 | 0,46% | الأسهم |
| PERCEPTIVE ADVISORS LLC | $40964900 | 170000 | 0,42% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $39434259 | 163648 | 0,40% | الأسهم |
| RHUMBLINE ADVISERS | $39282382 | 163018 | 0,40% | الأسهم |
| Holocene Advisors, LP | $38794001 | 160991 | 0,39% | الأسهم |
| Saturn V Capital Management LP | $38781230 | 160938 | 0,39% | الأسهم |
| PFM Health Sciences, LP | $38740265 | 160768 | 0,39% | الأسهم |
| Retirement Systems of Alabama | $38473993 | 159663 | 0,39% | الأسهم |
| Woodline Partners LP | $36165501 | 150083 | 0,37% | الأسهم |
| LOOMIS SAYLES & CO L P | $35355338 | 146721 | 0,36% | الأسهم |
| Pictet Asset Management Holding SA | $35115175 | 147599 | 0,36% | الأسهم |
| PRINCIPAL FINANCIAL GROUP INC | $34163762 | 141776 | 0,35% | الأسهم |
| STIFEL FINANCIAL CORP | $33583066 | 139365 | 0,34% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $33026625 | 137057 | 0,34% | الأسهم |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $32383478 | 134388 | 0,33% | الأسهم |
| California Public Employees Retirement System | $30759098 | 127647 | 0,31% | الأسهم |
| WEDGE CAPITAL MANAGEMENT L L P/NC | $30249134 | 160006 | 0,31% | الأسهم |
| Robeco Institutional Asset Management B.V. | $28340967 | 117612 | 0,29% | الأسهم |
| Gotham Asset Management, LLC | $26992014 | 112014 | 0,27% | الأسهم |
| Aristotle Capital Management, LLC | $26915626 | 111697 | 0,27% | الأسهم |
| Swiss National Bank | $26771767 | 111100 | 0,27% | الأسهم |
| STOREBRAND ASSET MANAGEMENT AS | $26309828 | 109183 | 0,27% | الأسهم |
| CANADA PENSION PLAN INVESTMENT BOARD | $25928372 | 107600 | 0,26% | الأسهم |
| PANAGORA ASSET MANAGEMENT INC | $25286187 | 104935 | 0,26% | الأسهم |
| BlackRock, Inc. | $23889284 | 99138 | 0,24% | الأسهم |
| Perpetual Ltd | $23733376 | 98491 | 0,24% | الأسهم |
| WELLINGTON MANAGEMENT GROUP LLP | $23658917 | 98182 | 0,24% | الأسهم |
| MORGAN STANLEY | $23519795 | 97604 | 0,24% | الأسهم |
| Man Group plc | $23299389 | 96690 | 0,24% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $22868053 | 94900 | 0,23% | عقد خيار البيع |
| ENVESTNET ASSET MANAGEMENT INC | $22061835 | 91554 | 0,22% | الأسهم |
| Rhenman & Partners Asset Management AB | $21070417 | 87440 | 0,21% | الأسهم |
| Aberdeen Group plc | $20146538 | 83606 | 0,20% | الأسهم |
| Amundi | $19114464 | 79323 | 0,19% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18916145 | 78500 | 0,19% | عقد خيار الشراء |
| Schonfeld Strategic Advisors LLC | $18620232 | 77272 | 0,19% | الأسهم |
| FIRST TRUST ADVISORS LP | $18149860 | 75320 | 0,18% | الأسهم |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $17765513 | 73725 | 0,18% | الأسهم |
| LAZARD ASSET MANAGEMENT LLC | $16768620 | 69588 | 0,17% | الأسهم |
| Longaeva Partners L.P. | $16576808 | 68792 | 0,17% | الأسهم |
| Simplify Asset Management Inc. | $16520903 | 68560 | 0,17% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $16497448 | 87265 | 0,17% | الأسهم |
| Distillate Capital Partners LLC | $16167159 | 67092 | 0,16% | الأسهم |
| SEB Asset Management AB | $15890255 | 65943 | 0,16% | الأسهم |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $15380484 | 64700 | 0,16% | الأسهم |
| SEI INVESTMENTS CO | $14931224 | 61963 | 0,15% | الأسهم |
| Illinois Municipal Retirement Fund | $14911947 | 61883 | 0,15% | الأسهم |
| Tweedy, Browne Co LLC | $14494105 | 60149 | 0,15% | الأسهم |
| MARTINGALE ASSET MANAGEMENT L P | $14335788 | 59492 | 0,15% | الأسهم |
| DeepCurrents Investment Group LLC | $14132168 | 58647 | 0,14% | الأسهم |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $13348774 | 55396 | 0,14% | الأسهم |
| VANGUARD ASSET MANAGEMENT, Ltd | $12952138 | 53750 | 0,13% | الأسهم |
| ExodusPoint Capital Management, LP | $12819845 | 53201 | 0,13% | الأسهم |
| Squarepoint Ops LLC | $12807074 | 53148 | 0,13% | الأسهم |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12034356 | 63657 | 0,12% | الأسهم |
| ALGERT GLOBAL LLC | $11749697 | 48760 | 0,12% | الأسهم |
| CASTLEARK MANAGEMENT LLC | $11306312 | 46920 | 0,11% | الأسهم |
| CITADEL ADVISORS LLC | $11253299 | 46700 | 0,11% | عقد خيار الشراء |
| RENAISSANCE GROUP LLC | $11221601 | 46568 | 0,11% | الأسهم |
| Nuveen, LLC | $11184623 | 46415 | 0,11% | الأسهم |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | $10859795 | 45067 | 0,11% | الأسهم |
| Foundry Partners, LLC | $10730160 | 86429 | 0,11% | الأسهم |
| Legal & General Group Plc | $10402916 | 43171 | 0,11% | الأسهم |
| DEAN INVESTMENT ASSOCIATES, LLC | $10273274 | 42633 | 0,10% | الأسهم |
المطلعون على الشركة 50 من المطلعين · مسؤولون 4 · مديرون 4
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Renee D Gala | President & CEO | 30 يونيو، 2026 F | 147361 | 0 | 0 | $0 |
| Philip L Johnson | EVP & Chief Financial Officer | 30 يونيو، 2026 F | 56431 | 0 | 0 | $0 |
| Neena M Patil | EVP & Chief Legal Officer | 30 يونيو، 2026 F | 48871 | 0 | 2 | $-560664 |
| Robert Iannone | EVP, Global Head of R&D & CMO | 30 يونيو، 2026 F | 85107 | 0 | 0 | $0 |
| Bryan C Cressey | مدير | 9 مارس، 2012 S | 27631 | 0 | 0 | $0 |
| Zilkha M Nathaniel | مدير | 10 مارس، 2011 A | — | 0 | 0 | $0 |
| Alexander E Albert | مدير | 15 أغسطس، 2008 A | — | 0 | 0 | $0 |
| Patel Jaimin | مدير | 15 أغسطس، 2007 A | — | 0 | 0 | $0 |
| Patrick Kennedy | — | 5 أغسطس، 2026 A | 8307 | 0 | 0 | $0 |
| Samantha Pearce | — | 5 أغسطس، 2026 F | 47131 | 0 | 1 | $-1625977 |
| Mark Douglas Smith | — | 5 أغسطس، 2026 A | 11285 | 0 | 1 | $-266746 |
| Jennifer E. Cook | — | 5 أغسطس، 2026 A | 12442 | 0 | 0 | $0 |
| Laura Hamill | — | 5 أغسطس، 2026 A | 8538 | 0 | 0 | $0 |
| Heather Ann Mcsharry | — | 5 أغسطس، 2026 A | 20054 | 0 | 0 | $0 |
| Seamus Mulligan | — | 5 أغسطس، 2026 A | 1184633 | 0 | 0 | $0 |
| Rick E Winningham | — | 5 أغسطس، 2026 A | 11172 | 0 | 2 | $-1656873 |
| Patrick G. Enright | — | 5 أغسطس، 2026 A | 22984 | 0 | 0 | $0 |
| Bruce C Cozadd | — | 5 أغسطس، 2026 A | 362287 | 0 | 20 | $-25646326 |
| Ted W Love | — | 5 أغسطس، 2026 A | 3132 | 0 | 0 | $0 |
| Norbert G Riedel | — | 5 أغسطس، 2026 A | 8629 | 0 | 1 | $-655680 |
| Kenneth W O'Keefe | — | 2 ديسمبر، 2025 F | 25811 | 0 | 0 | $0 |
| Daniel N Swisher JR | — | 3 يناير، 2019 F | 16512 | 0 | 0 | $0 |
| Suzanne Sawochka Hooper | — | 14 ديسمبر، 2018 M | 41184 | 0 | 0 | $0 |
| Matthew P. Young | — | 23 نوفمبر، 2018 S | 32068 | 0 | 0 | $0 |
| MILLER MICHAEL PATRICK | — | 13 نوفمبر، 2018 S | 24972 | 0 | 0 | $0 |
| Paul Treacy | — | 10 أغسطس، 2018 S | 17458 | 0 | 0 | $0 |
| Elmar Schnee | — | 9 أغسطس، 2018 A | 6094 | 0 | 0 | $0 |
| Peter Gray | — | 9 أغسطس، 2018 A | 8182 | 0 | 0 | $0 |
| Catherine A. Sohn | — | 9 أغسطس، 2018 A | 7654 | 0 | 0 | $0 |
| Paul L Berns | — | 9 أغسطس، 2018 A | 6772 | 0 | 0 | $0 |
| Karen J Wilson | — | 11 مايو، 2018 S | 15757 | 0 | 0 | $0 |
| Karen L. Smith | — | 5 مارس، 2018 F | 28474 | 0 | 0 | $0 |
| Iain Mcgill | — | 5 مارس، 2018 F | 22048 | 0 | 0 | $0 |
| Russell J. Cox | — | 6 مارس، 2017 F | 52795 | 0 | 0 | $0 |
| Jeffrey K Tobias | — | 5 مارس، 2015 F | 38484 | 0 | 0 | $0 |
| Fintan Keegan | — | 8 يوليو، 2014 M | 31750 | 0 | 0 | $0 |
| Kathryn E Falberg | — | 5 مارس، 2014 F | 133387 | 0 | 0 | $0 |
| James C Momtazee | — | 13 أغسطس، 2013 S | 17315 | 0 | 0 | $0 |
| Carol A Gamble | — | 9 مارس، 2012 S | 32213 | 0 | 0 | $0 |
| Alan Sebulsky | — | 9 مارس، 2012 S | 54355 | 0 | 0 | $0 |
| Samuel D Colella | — | 11 يناير، 2012 M | 38347 | 0 | 0 | $0 |
| Michael W Michelson | — | 11 يناير، 2012 M | 13885 | 0 | 0 | $0 |
| Mark G. Eller | — | 13 أغسطس، 2011 M | 4151 | 0 | 0 | $0 |
| Michael A. Desjardin | — | 13 أغسطس، 2011 M | 14574 | 0 | 0 | $0 |
| Janne Lt Wissel | — | 31 مايو، 2011 J | 48544 | 0 | 0 | $0 |
| Joan Colligan | — | 30 نوفمبر، 2010 J | 14424 | 0 | 0 | $0 |
| Robert M Myers | — | 30 نوفمبر، 2010 J | 156898 | 0 | 0 | $0 |
| James B Tananbaum | — | 25 أغسطس، 2010 A | 21366 | 0 | 0 | $0 |
| Samuel R Saks | — | 21 يناير، 2009 A | 358868 | 0 | 0 | $0 |
| Matthew K Fust | — | 28 نوفمبر، 2008 J | 58948 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 6 حيازات
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public Limited Company, Jazz Financing I Limited, Jazz Investments II Limited, Jazz Pharmaceuticals Italy S.p.A. ×4 إيداعات | 20 يونيو، 2014 | — | إيداع أولي | — | SEC |
| KKR JP LLC, KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, KKR JP III LLC, KKR Partners III, L.P., KKR III GP LLC, Henry R. Kravis, George R. Roberts ×3 إيداعات | 12 مارس، 2013 | — | إيداع أولي | — | SEC |
| Longitude Capital Partners, LLC, Longitude Venture Partners, L.P., Longitude Capital Associates, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×3 إيداعات | 14 مارس، 2012 | — | إيداع أولي | — | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) ×3 إيداعات | 30 سبتمبر، 2011 | — | إيداع أولي | — | SEC |
| Azur Pharma Limited | 28 سبتمبر، 2011 | — | إيداع أولي | — | SEC |
| Jazz Pharmaceuticals, Inc., KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Partners III, L.P., KKR III GP LLC, KKR JP LLC, KKR JP III LLC | 28 إبريل، 2005 | — | إيداع أولي | اندماج واستحواذ / بيع | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 72 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| IHE · iShares Trust | 3,55% | 224123 SH | 8 أغسطس، 2026 | يومي |
| PJP · Invesco Exchange-Traded Fund Trust | 2,75% | 54246 SH | 8 أغسطس، 2026 | يومي |
| PTH · Invesco Exchange-Traded Fund Trust | 1,88% | 18101 SH | 8 أغسطس، 2026 | يومي |
| PILL · Direxion Shares ETF Trust | 1,47% | 931 NS | 30 إبريل، 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,10% | 3412 SH | 8 أغسطس، 2026 | يومي |
| RFG · Invesco Exchange-Traded Fund Trust | 1,01% | 14167 SH | 8 أغسطس، 2026 | يومي |
| IJK · iShares Trust | 0,86% | 367117 SH | 8 أغسطس، 2026 | يومي |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,79% | 61910 SH | 8 أغسطس، 2026 | يومي |
| PDP · Invesco Exchange-Traded Fund Trust | 0,64% | 37430 SH | 8 أغسطس، 2026 | يومي |
| XJH · iShares Trust | 0,51% | 8479 SH | 8 أغسطس، 2026 | يومي |
| ISCV · iShares Trust | 0,50% | 13756 SH | 8 أغسطس، 2026 | يومي |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,50% | 14803 NS | 30 إبريل، 2026 | N-PORT |
| AVMV · AMERICAN CENTURY ETF TRUST | 0,49% | 12809 NS | 31 مايو، 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,48% | 8322 SH | 8 أغسطس، 2026 | يومي |
| IJH · iShares Trust | 0,44% | 2164793 SH | 8 أغسطس، 2026 | يومي |
| SMMV · iShares Trust | 0,41% | 4673 SH | 8 أغسطس، 2026 | يومي |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,41% | 101353 SH | 8 أغسطس، 2026 | يومي |
| VFVA · VANGUARD WELLINGTON FUND | 0,32% | 11363 SH | 8 أغسطس، 2026 | يومي |
| VBR · VANGUARD INDEX FUNDS | 0,31% | 867777 SH | 8 أغسطس، 2026 | يومي |
| AVLV · AMERICAN CENTURY ETF TRUST | 0,28% | 154718 NS | 31 مايو، 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,28% | 8083 SH | 8 أغسطس، 2026 | يومي |
| IYH · iShares Trust | 0,25% | 35721 SH | 8 أغسطس، 2026 | يومي |
| ISCB · iShares Trust | 0,25% | 2794 SH | 8 أغسطس، 2026 | يومي |
| DFAS · Dimensional ETF Trust | 0,25% | 169973 NS | 30 إبريل، 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,24% | 1006 NS | 30 إبريل، 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,24% | 19561 SH | 8 أغسطس، 2026 | يومي |
| NUSC · Nushares ETF Trust | 0,23% | 14796 NS | 30 إبريل، 2026 | N-PORT |
| ESML · iShares Trust | 0,23% | 25562 SH | 8 أغسطس، 2026 | يومي |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,20% | 3508 NS | 31 مايو، 2026 | N-PORT |
| SMMD · iShares Trust | 0,20% | 29882 SH | 8 أغسطس، 2026 | يومي |
| VHT · VANGUARD WORLD FUND | 0,20% | 166548 SH | 8 أغسطس، 2026 | يومي |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,20% | 10307 SH | 8 أغسطس، 2026 | يومي |
| VXF · VANGUARD INDEX FUNDS | 0,17% | 719903 SH | 8 أغسطس، 2026 | يومي |
| VB · VANGUARD INDEX FUNDS | 0,17% | 1366973 SH | 8 أغسطس، 2026 | يومي |
| DFAT · Dimensional ETF Trust | 0,17% | 113983 NS | 30 إبريل، 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,16% | 59597 NS | 30 إبريل، 2026 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,15% | 1679 NS | 31 مايو، 2026 | N-PORT |
| IWS · iShares Trust | 0,15% | 89654 SH | 8 أغسطس، 2026 | يومي |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,14% | 59 NS | 31 مايو، 2026 | N-PORT |
| WSML · iShares Trust | 0,13% | 3473 SH | 8 أغسطس، 2026 | يومي |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,13% | 2492 NS | 31 مايو، 2026 | N-PORT |
| IWR · iShares Trust | 0,11% | 243081 SH | 8 أغسطس، 2026 | يومي |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 3276 SH | 8 أغسطس، 2026 | يومي |
| XT · iShares Trust | 0,09% | 13696 SH | 8 أغسطس، 2026 | يومي |
| AVLC · AMERICAN CENTURY ETF TRUST | 0,08% | 4239 NS | 31 مايو، 2026 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,08% | 42911 NS | 31 مايو، 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,07% | 2294 NS | 31 مايو، 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,07% | 147813 NS | 30 إبريل، 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,06% | 45962 NS | 30 إبريل، 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,05% | 7081 NS | 30 إبريل، 2026 | N-PORT |